Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Epiphyseal dysplasia-hearing loss-dysmorphism syndrome is a rare multiple congenital anomalies/dysmorphic syndrome characterized by developmental delay, intellectual disability, short stature, sensorineural hearing impairment, facial dysmorphism (incl. epicanthus, broad, depressed nasal bridge, broad, fleshy nasal tip, mildly anteverted nares, deep nasolabial folds, broad mouth with thin upper lip) and skeletal anomalies (incl. abnormally placed thumbs, brachydactyly, scoliosis, dysplastic carpal bones). Patients also present severe behavior disturbances (aggression, hyperactivity), as well as hypopigmented skin lesions and hypoplastic digital patterns. There have been no further descriptions in the literature since 1992.
Biomarker and diagnostic research for epiphyseal dysplasia-hearing loss-dysmorphism syndrome has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for epiphyseal dysplasia-hearing loss-dysmorphism syndrome.
171 publications have been identified in PubMed for epiphyseal dysplasia-hearing loss-dysmorphism syndrome. Kisho has analyzed 103 by research type. Research spans Review / Meta-Analysis (38%), Case Report / Case Series (28%), and Basic Science / Preclinical (16%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 39 | 38% |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 5:41 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Patient case studies |
29 |
28% |
Laboratory research | 16 | 16% |
Clinical study results | 10 | 10% |
Disease patterns and progression | 5 | 5% |
Other research | 2 | 2% |
Testing and diagnosis research | 2 | 2% |
Liang C (2026). [PMID: 41810204](https://pubmed.ncbi.nlm.nih.gov/41810204/). *Transl Pediatr*. [Case Report / Case Series]
Sánchez CMD (2026). [PMID: 41052910](https://pubmed.ncbi.nlm.nih.gov/41052910/). *Clin Genet*. [Case Report / Case Series]
Saeki N (2026). [PMID: 40995872](https://pubmed.ncbi.nlm.nih.gov/40995872/). *Dev Dyn*. [Review / Meta-Analysis]
Echevarría-Marín MI (2026). [PMID: 42229480](https://pubmed.ncbi.nlm.nih.gov/42229480/). *Acta Ortop Mex*. [Review / Meta-Analysis]
Zhou Q (2026). [PMID: 41772121](https://pubmed.ncbi.nlm.nih.gov/41772121/). *Langenbecks Arch Surg*. [Clinical Trial Publication]
Singh J (2026). [PMID: 42055752](https://pubmed.ncbi.nlm.nih.gov/42055752/). *BMJ Case Rep*. [Case Report / Case Series]
Pattani N (2026). [PMID: 41956799](https://pubmed.ncbi.nlm.nih.gov/41956799/). *J Med Genet*. [Case Report / Case Series]
Liu M (2026). [PMID: 41400824](https://pubmed.ncbi.nlm.nih.gov/41400824/). *Virulence*. [Basic Science / Preclinical]
Deng Q (2026). [PMID: 42170480](https://pubmed.ncbi.nlm.nih.gov/42170480/). *Am J Transl Res*. [Case Report / Case Series]
Davies LM (2026). [PMID: 41731457](https://pubmed.ncbi.nlm.nih.gov/41731457/). *BMC Pediatr*. [Review / Meta-Analysis]